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Abstract
Background: To test the hypothesis that point-of-care assays of platelet reactivity would
demonstrate reduced response to antiplatelet therapy in patients who experienced Drug Eluting
Stent (DES) ST whilst on dual antiplatelet therapy compared to matched DES controls. Whilst the
aetiology of stent thrombosis (ST) is multifactorial there is increasing evidence from laboratory-
based assays that hyporesponsiveness to antiplatelet therapy is a factor in some cases.
Methods: From 3004 PCI patients, seven survivors of DES ST whilst on dual antiplatelet therapy
were identified and each matched with two patients without ST. Analysis was performed using (a)
short Thrombelastogram PlateletMapping™ (TEG) and (b) VerifyNow Aspirin and P2Y12 assays.
TEG analysis was performed using the Area Under the Curve at 15 minutes (AUC15) as previously
described.
Results: There were no differences in responses to aspirin. There was significantly greater platelet
reactivity on clopidogrel in the ST group using the Accumetrics P2Y12 assay (183 ± 51 vs. 108 ±
31, p = 0.02) and a trend towards greater reactivity using TEG AUC15 (910 ± 328 vs. 618 ± 129,
p = 0.07). 57% of the ST group by TEG and 43% of the ST cases by Accumetrics PRU had results
> two standard deviations above the expected mean in the control group.
Conclusion: This study demonstrates reduced platelet response to clopidogrel in some patients
with DES ST compared to matched controls. The availability of point-of-care assays that can detect
these responses raises the possibility of prospectively identifying DES patients at risk of ST and
manipulating their subsequent risk.
Background
Robust evidence demonstrating the ability of drug-eluting
stent (DES) technology to reduce restenosis in compari-
son to bare metal stents (BMS) has led to widespread DES
uptake. Balanced against this significant clinical benefit,
however, is concern about the incidence of stent throm-
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domised trial data suggest that there is a cumulative
incidence of ST in DES patients of between 0.5%–1% per
year [1,2], correlating in some series with a similar rate of
death and myocardial infarction [3].
There are well established procedural risk factors for ST
such as stent under-deployment [4], length of stented seg-
ment [5], and idiosyncratic factors including a form of
hypersensitivity [6]. However, the inappropriate termina-
tion of aspirin and clopidogrel therapy appears to be par-
ticularly hazardous [7]. In DES patients there is therefore
an important reliance for some (as yet undetermined)
period of time on dual antiplatelet therapy [8,9], possibly
as a result delayed stent endothelialisation [10]. This
requirement for ongoing dual antiplatelet therapy,
together with evidence of considerable biological variabil-
ity in the response of individuals to antiplatelet therapies,
particularly clopidogrel [11,12], and association between
poor response and adverse cardiovascular outcome
[13,14] has raised the important question: can poor
responses to these agents render some individuals at risk
of DES ST? There is now growing evidence from labora-
tory based assays that variability in the response to
antiplatelet agents, particularly clopidogrel, can contrib-
ute to ST in DES patients [15-21].
Typically, clopidogrel is given in standard doses to
patients receiving DES, despite both experimental and
clinical data demonstrating important biological varia-
tion in response. However, clinical detection of reduced
responsiveness to clopidogrel and/or aspirin has been
hampered both by a lack of point-of-care assays and by an
appropriate definition of what constitutes "resistance"
[22].
The purpose of this study was to test the hypothesis that
platelet reactivity whilst on aspirin and clopidogrel,
assessed using two near patient assays, a novel modifica-
tion of Thrombelastograph® (TEG) PlateletMapping™ [23]
and Accumetrics VerifyNow™, would be significantly
greater in a consecutive group of patients who survived
DES ST than in matched DES controls.
Methods
Study Population
Approval was obtained from the Isle of Wight, Port-
smouth & South East Hampshire Research Ethics commit-
tee prior to commencing the study (Ref: 06/Q1701/49).
All subjects provided written informed consent.
Twenty-two patients with DES ST were identified from a
consecutive series of 3004 patients, 90% of whom
received DES, over a 2 year period at this centre [24].
Seven cases (four subacute and three late) were identified
where ST occurred in the context of dual antiplatelet ther-
apy with both aspirin and clopidogrel and in whom dual
antiplatelet therapy was on-going. None of the cases were
taking additional antiplatelet therapy, anticoagulants or
non-steroidal anti inflammatory medication.
For each case two control patients were identified from
the interventional database, and individually matched
according to duration and dose of antiplatelet therapy,
gender, age, smoking, diabetes, initial presentation and
procedure undertaken. A summary of the demographics
and baseline haematological variables of the cases and
controls is given in Tables 1 and 2.
Venesection
In all subjects venesection was performed from the
antecubital fossa using an 18 gauge needle and a lightly
applied tourniquet and the first 2 mls of blood discarded.
Table 1: Demographics
ST cases Individual Controls p value
Age 61.9 ± 5.7 61.8 ± 4.3 N/S
Sex (% Male) 86 86 N/S
Smokers (%) 42.9 35.7 N/S
Diabetes (%) 14.3 14.3 N/S
Emergency cases (%) 14.3 14.3 N/S
Elective cases (%) 14.3 33.3 N/S
ACS cases (%) 71.4 52.4 N/S
Stent length (mm) 26.7 ± 11.3 27.9 ± 6.3 N/S
Minimum stent diameter (mm) 2.8 ± 0.3 2.9 ± 0.3 N/S
Aspirin dose (mg) 140 ± 21.0 140 ± 13.4 N/S
Clopidogrel dose (mg) 86 ± 21 75 N/S
Duration of clopidogrel (days) 161 ± 163 77 ± 28 N/S
Time from latest event/intervention (days) 145 ± 84 76 ± 28 N/S
Statin (% total/% Atorvastatin) 100/14 100/7 N/S
Summary of demographics in the seven cases and 14 controls. There are no significant differences between the groups.Page 2 of 6
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tainer® for TEG analysis and two 2 ml 3.2% sodium citrate
Vacutainers® for VerifyNow analysis.
Sample analysis
TEG
samples were analysed using TEG PlateletMapping™
(Haemoscope Corp, IL, USA) according to the manufac-
turer's instructions. For each trace the maximum ampli-
tude (MA) was obtained from the standard analysis
package and the Area under the response curve at 15 min-
utes (AUC15) calculated using a software programme
(Areafinder 2:1) and method of analysis developed and
previously described by this group [23,25].
VerifyNow
VerifyNow™ Aspirin and P2Y12 assays were analysed for
each individual according to manufacturer's instructions
to obtain the aspirin response units (ARU) and platelet
response units (PRU) respectively.
Result analysis
For TEG samples comparisons were made between the
MA and AUC15 for each individual channel in the 2
groups. The percentage platelet inhibition (%PIn) and
percentage clotting inhibition (%CIn) were calculated for
both aspirin (using the channel with Arachidonic Acid
(AA) stimulation) and clopidogrel (using Adenosine
DiPhosphate (ADP) stimulation) from each sample
[23,26]. For Accumetrics comparisons were made
between the ARU and PRU.
Statistics
Expert statistical advice was obtained prior to the com-
mencement of the study. Data are presented as the mean
and 95% confidence interval of the mean. Significance
between the groups was determined using two group t-
tests for continuous variables and χ2 (chi squared) tests
for categorical data with a p value of < 0.05 (2-tailed) con-
sidered to represent significance.
Results
Baseline demographics are shown in Table 1. There were
no significant differences between the 2 groups which
were well matched, nor were there any significant differ-
ences in baseline haematological variables between the 2
groups (Table 2).
Responses to aspirin
TEG
There was no significant difference in responses assessed
with AA-stimulation between the ST group and control
group in (i) %PIn (79.6 ± 20.8 vs. 89.9 ± 7.6, p = 0.39);
%CIn (75.2 ± 9.4 vs. 75.9 ± 6.0, p = 0.90); (ii) MA of the
AA channel (25.3 ± 17.6 vs. 14.0 ± 4.5, p = 0.26) or (iii)
AUC15 of the AA channel (244 ± 113 vs. 216 ± 56, p =
0.67).
VerifyNow
There was no significant difference between ARU meas-
urements in the ST group and controls (453 ± 50 vs 410 ±
29, p = 0.18).
Responses to Clopidogrel
TEG
There was no significant difference between the ST group
and controls in the %PIn due to Clopidogrel (18.2 ± 33.2
vs. 31.8 ± 13.2, p = 0.38); the %CIn (5.6 ± 27.7 vs. 30.6 ±
13.4, p = 0.09 or the MA of the ADP channel (50.5 ± 15.8
vs. 46.0 ± 7.5, p = 0.62). There was trend towards signifi-
cance with the AUC of the ADP channel (910 ± 329 vs.
618 ± 130, p = 0.07) with 57% (4 of 7) of the ST group
compared to 0% of controls having an AUC > 1100 (AUC
> 2 standard deviations above the mean of the control
group) (See Figure 1).
Other TEG variables
There were no significant differences between cases and
controls in TEG variables which have been previously
identified as predictive of ischaemic events after PCI (i.e.
MA of the Thrombin channel (61.6 ± 2.9 vs. 64.1 ± 2.7, p
= 0.21) and the R time of the Thrombin channel (6.9 ± 1.5
vs. 7.1 ± 2.0, p = 0.84)) [14].
VerifyNow
The PRU in the ST group was significantly higher than in
controls (183 ± 51 vs. 108 ± 31, p = 0.02). 43% (3 of 7) of
the ST cases compared to 0% of controls had PRU > 225
(PRU > 2 standard deviations above the mean of the con-
trol group) (See Figure 2).
Discussion
The hypothesis for this study was that these two point-of-
care tests (VerifyNow and a novel modification of TEG
that produces a result after only 15 minutes) could detect
reduced responsiveness to antiplatelet therapy in survi-
vors of ST whilst on dual antiplatelet therapy compared to
matched controls. This hypothesis has been disproved in
the case of aspirin but proved for clopidogrel using Accu-
Table 2: Haematological variables
ST cases Controls p value
Hb conc. (g/l) 130 ± 13 137 ± 10 0.30
Haematocrit (%) 0.39 ± 0.03 0.40 ± 0.03 0.44
Platelet count 262 ± 42 229 ± 25 0.35
INR 1.1 ± 0.1 1.0 ± 0.0 0.15
eGFR (mls/min) 67 ± 8 64 ± 4 0.64
Haematological variables. There were no significant differences 
between the two groups.Page 3 of 6
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AUC15. Our results suggest that clopidogrel, but not aspi-
rin, resistance contributes to ST in some cases.
Implications
The implications of this study are clinically relevant.
Firstly, they add to the growing concern that some
patients receiving DES may be intrinsically at risk of ST
because of their relative lack of response to clopidogrel.
Secondly, there are now two point-of-care assays available
that allow rapid detection of the response of prospective
DES patients to clopidogrel, raising the possibility that
such "at risk" individuals could be detected in routine
clinical practice, before they are exposed to the potentially
suboptimal combination of DES and standard doses of
antiplatelet drugs. We found that approximately 50% of
patients with previous ST whilst on clopidogrel had
abnormally high reactivity whilst on clopidogrel with
both Accumetrics and TEG (PRU and TEG AUC15 of ADP
channel > 2 standard deviations above the expected
means). Further data are now required to determine (a)
whether the responses of such individuals to antiplatelet
therapy can be normalised by interventions such as
increasing the maintenance dose of clopidogrel [27], or
TEG ResultsFigure 1
TEG Results. The AUC15 of the ADP channel in the ST group and in matched controls. Whilst there was no significant dif-
ference between the two groups (910 ± 329 vs. 618 ± 130, p = 0.07) Four of the five greatest responses (signifying the least 
response to clopidogrel) occurred in the ST group. {AUC15 – area under the response curve at 15 minutes; ADP – Adenosine 
Diphosphate; ST – Stent thrombosis}.
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Accumetrics ResultsFig re 2
Accumetrics Results. VerifyNow PRU in the ST group and in matched controls. Mean PRU was significantly higher in the ST 
group than in matched controls ((183 ± 51 vs. 108 ± 31, p = 0.02)). The five greatest responses (signifying the least response to 
clopidogrel) all occurred in the ST group. {PRU – Platelet Reaction Units; ST – Stent Thrombosis}.
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agents [28,29], and (b) whether prospectively screening
large populations of patients undergoing percutaneous
intervention using such tests to guide therapy can decrease
ST rates.
Study limitations
This study has important limitations. Firstly, the absolute
number of ST patients is low. Nevertheless, the ST popu-
lation in this study was derived from a consecutive series
of 3004 DES patients at a single centre. Secondly, as this is
a retrospective study we do not have baseline samples
prior to the initiation of antiplatelet therapy for calcula-
tion of a response to antiplatelet therapy compared to
baseline. Instead we utilised the clinically important
measure of platelet reactivity whilst on antiplatelet treat-
ment. Thirdly, studies recruiting patients who have sur-
vived ST will inevitably be weaker for the absence of data
relating to patients who died as a result of ST. Lastly we
did not test for evidence of drug compliance in this study.
Conclusion
Using assays suitable for point-of-care use in routine clin-
ical practice, this study demonstrates an association
between reduced responses to clopidogrel, but not aspi-
rin, in a proportion of DES ST patients when compared to
matched DES patients without ST. These findings are in
keeping with recent studies using laboratory based
research tools. The availability of two point-of-care assays
that can be employed to detect such responses raises the
possibility of detecting clopidogrel hypo-responsiveness
prior to DES implantation and possibly manipulating the
risk of subsequent ST. Further data are required.
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